Oxidative stress and disturbed glutamate transport in spinal muscular atrophy.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Brain & development (Tokyo. 1979)

• Publication date

  2002-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0387-7604(02)00103-1PMID 12453601
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oxidative Damage Is the Earliest Event in Alzheimer Disease

  2001cited by this paper
• Oxidative Stress and Disturbed Glutamate Transport in Hereditary Nucleotide Repair Disorders

  2001cited by this paper
• Ultrastructural Analysis and TUNEL Demonstrate Motor Neuron Apoptosis in Werdnig‐Hoffmann Disease

  2000cited by this paper
• Reactive oxygen species‐induced molecular damage and its application in pathology

  1999cited by this paper
• Do the benefits of currently available treatments justify early diagnosis and treatment of amyotrophic lateral sclerosis? Arguments against.

  1999cited by this paper
• Molecular diagnosis of spinal muscular atrophy

  1998cited by this paper
• A study of cell death in Werdnig Hoffmann disease brain.

  1998cited by this paper
• Glutamate Transporter Alterations in Alzheimer Disease Are Possibly Associated with Abnormal APP Expression

  1997cited by this paper
• Distribution of Glutamate Transporter Subtypes During Human Brain Development

  1997cited by this paper
• Increased 3‐nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis

  1997cited by this paper
• 4‐Hydroxynonenal‐Derived Advanced Lipid Peroxidation End Products Are Increased in Alzheimer's Disease

  1997cited by this paper
• Muscle Disorders in Childhood, 2nd Ed.

  1996cited by this paper
• Immunohistochemical study of advanced glycation end products in aging and Alzheimer's disease brain.

  1996cited by this paper
• Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.

  1996cited by this paper
• The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy.

  1995cited by this paper
• Identification and characterization of a spinal muscular atrophy-determining gene

  1995cited by this paper
• Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis

  1995cited by this paper
• Localization of neuronal and glial glutamate transporters.

  1994cited by this paper
• Muscle disorders in childhood.

  1977cited by this paper

• Nusinersen rescues taurine deficiency in patients with type 1 Spinal Muscular Atrophy.

  2026cites this paper
• MiR-140-3p regulates axonal motor protein KIF5A and contributes to axonal transport degeneration in SMA

  2025cites this paper
• Physiological Features of the Neural Stem Cells Obtained from an Animal Model of Spinal Muscular Atrophy and Their Response to Antioxidant Curcumin

  2024cites this paper
• Dysregulation of cerebrospinal fluid metabolism profiles in spinal muscular atrophy patients: a case control study

  2024cites this paper
• Genetic Variability in Oxidative Stress, Inflammatory, and Neurodevelopmental Pathways: Impact on the Susceptibility and Course of Spinal Muscular Atrophy

  2024cites this paper
• NADPH oxidase 4 inhibition is a complementary therapeutic strategy for spinal muscular atrophy

  2023cites this paper
• Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology

  2022cites this paper
• Induction of Survival of Motor Neuron (SMN) Protein Deficiency in Spinal Astrocytes by Small Interfering RNA as an In Vitro Model of Spinal Muscular Atrophy

  2022cites this paper
• Combining multiomics and drug perturbation profiles to identify Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy muscle-specific treatments for spinal muscular atrophy Let us know how access to this document benefits you.

  2022cites this paper
• Ceftriaxone as a Novel Therapeutic Agent for Hyperglutamatergic States: Bridging the Gap Between Preclinical Results and Clinical Translation

  2022cites this paper
• Mitochondrial Dysfunction in Spinal Muscular Atrophy

  2022cites this paper
• Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients

  2021cites this paper
• Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy

  2021cites this paper
• Revisiting the role of mitochondria in spinal muscular atrophy

  2021cites this paper
• Exercise-Related Oxidative Stress as Mechanism to Fight Physical Dysfunction in Neuromuscular Disorders

  2020influential citation
• Survival Motor Neuron Protein Modulates Lysosomal Function Through the Expression of Transcription Factor EB in Motoneurons

  2020cites this paper
• Combining multi-omics and drug perturbation profiles to identify novel treatments that improve disease phenotypes in spinal muscular atrophy

  2019cites this paper
• A SMN2 Splicing Modifier Rescues the Disease Phenotypes in an In Vitro Human Spinal Muscular Atrophy Model

  2019cites this paper
• Drug screening with human SMN2 reporter identifies SMN protein stabilizers to correct SMA pathology

  2019cites this paper
• Loss of cerebellar glutamate transporters EAAT4 and GLAST differentially affects the spontaneous firing pattern and survival of Purkinje cells

  2018cites this paper
• Leserbrief

  2018cites this paper
• Do Perineuronal Net Elements Contribute to Pathophysiology of Spinal Muscular Atrophy? In Vitro and Transcriptomics Insights

  2018cites this paper
• Spinal Muscular Atrophy Disease Modifiers

  2017cites this paper
• Edaravone is a candidate agent for spinal muscular atrophy: In vitro analysis using a human induced pluripotent stem cells‐derived disease model

  2017cites this paper
• Vascular Defects and Spinal Cord Hypoxia in Spinal Muscular Atrophy

  2016cites this paper
• DMM021766 39..49

  2016cites this paper
• Abnormal mitochondrial transport and morphology as early pathological changes in human models of spinal muscular atrophy

  2016cites this paper
• Oxidative Stress and Overview of Pediatric Disease Biomarkers

  2015cites this paper
• ventilator-induced lung injury Gene expression profiling of target genes in

  2015cites this paper
• Changes in Cerebrospinal Fluid Biomarkers in Human Herpesvirus-6-Associated Acute Encephalopathy/Febrile Seizures

  2014cites this paper
• Examining mechanisms underlying the selective vulnerability of motor units in a mouse model of Spinal Muscular Atrophy

  2014cites this paper
• ROCK inhibition as a therapy for spinal muscular atrophy: understanding the repercussions on multiple cellular targets

  2014cites this paper
• The Smn-Independent Beneficial Effects of Trichostatin A on an Intermediate Mouse Model of Spinal Muscular Atrophy

  2014cites this paper
• Antibiotics acting as neuroprotectants via mechanisms independent of their anti-infective activities.

  2013cites this paper
• Partial restoration of cardio-vascular defects in a rescued severe model of spinal muscular atrophy.

  2012cites this paper
• Spinal muscular atrophy: An oxidative stress response counteracted with curcumin

  2012cites this paper
• Identification of Novel Roles for the Survival Motor Neuron (Smn) Protein: Implications on Spinal Muscular Atrophy (SMA) Pathogenesis and Therapy

  2012cites this paper
• Oxidative stress in developmental brain disorders.

  2012cites this paper
• Étude des voies de signalisation impliquées dans le contrôle de l’expression de SMN dans des modèles murins d’Amyotrophie Spinale Infantile

  2012cites this paper
• Altered Gene Expression, Mitochondrial Damage and Oxidative Stress: Converging Routes in Motor Neuron Degeneration

  2012influential citation
• Identification of a Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitor, BIP-135, that Prolongs the Median Survival Time of Δ7 SMA KO Mouse Model of Spinal Muscular Atrophy.

  2012cites this paper
• Abnormal fatty acid metabolism in spinal muscular atrophy may predispose to perioperative risks.

  2012cites this paper
• Oxidative stress markers and phosphorus magnetic resonance spectroscopy in a patient with GLUT1 deficiency treated with modified Atkins diet.

  2012cites this paper
• The protective effects of β-lactam antibiotics in motor neuron disorders.

  2011cites this paper
• Inflammation in ALS and SMA: sorting out the good from the evil.

  2010cites this paper
• Is developmental neuropathology of the motor neurons the key to resolving the mystery in motor neuron diseases?

  2010cites this paper
• Diagnostic and Therapeutic Significance of the Oxidative Stress Parameters in Children

  2010cites this paper
• Trends in the Molecular Pathogenesis and Clinical Therapeutics of Common Neurodegenerative Disorders

  2009cites this paper
• Oxidative stress in developmental brain disorders

  2009cites this paper
• Histone Deacetylase Inhibition Activity and Molecular Docking of (E )‐Resveratrol: Its Therapeutic Potential in Spinal Muscular Atrophy

  2009cites this paper
• Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy.

  2008cites this paper
• Roles of oxidative stress in xeroderma pigmentosum.

  2008cites this paper
• Exogenous Hsc70, but not thermal preconditioning, confers protection to motoneurons subjected to oxidative stress

  2008cites this paper
• Oxidative stress in neurodegeneration in dentatorubral-pallidoluysian atrophy.

  2008cites this paper
• Chapter 5 Cytopathology of the motor neuron.

  2007cites this paper
• Biomarkers for oxidative stress: clinical application in pediatric medicine.

  2007cites this paper
• Gene expression profiling of target genes in ventilator-induced lung injury.

  2006cites this paper
• Protracted juvenile neuronal ceroid lipofuscinosis--an autopsy report and immunohistochemical analysis.

  2006cites this paper
• Mechanisms of neurodegeneration in neuronal ceroid-lipofuscinoses

  2006cites this paper
• SMN, the product of the spinal muscular atrophy‐determining gene, is expressed widely but selectively in the developing human forebrain

  2006cites this paper
• Neurofibrillary tangles and deposition of oxidative products in the brain in cases of myotonic dystrophy

  2006cites this paper
• TNFα potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NFκB inhibition

  2005cites this paper
• TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition.

  2005cites this paper
• Oxidative nucleotide damage and superoxide dismutase expression in the brains of xeroderma pigmentosum group A and Cockayne syndrome.

  2005cites this paper
• Infantile bilateral striatal necrosis maps to chromosome 19q

  2004cites this paper
• Thalamic lesions in a long-surviving child with spinal muscular atrophy type I: MRI and EEG findings.

  2004cites this paper
• Neuropathological analysis in spinal muscular atrophy type II

  2003cites this paper